(Source: Ergomed plc) PRESS RELEASE FOR IMMEDIATE RELEASE Ergomed announces positive Phase II top-line results of co-development partner Ferrer's Lorediplon for the treatment of insomnia London, UK - 6 Febuary 2017:Ergomed plc (LSE: ERGO) ('Ergomed' or 'the Company'), a company dedicated to the provision of specialised services to the pharmaceutical industry and the development of new drugs, today announces positive top-line results from a Phase II clinical trial of Lorediplon in patients with insomnia with its co-development partner Ferrer. Highlights: · Both 5 and 10mg Lorediplon met the primary endpoint with high statistical significance, indicating the drug has strong efficacy in sleep...
↧
